Road to a Cure - Dr. Heather Parsons & Dr. Nancy Lin
The Road to a Cure series heads to Boston to have Senior Producer and Co-host, Victoria Goldberg and co-host Dr. Paula Jayne speak with Dr. Nancy Lin and Dr. Heather Parsons about the possibilities and the current barriers to considering a cure for HER2+ MBC. Dr. Parsons and Dr. Lin are medical oncologists and professors at Harvard Medical School. Dr. Lin is also the Director of the Metastatic Breast Cancer Program and the Associate Chief of the Division of Breast Oncology at Dana Farber Cancer Institute. While an amazing gift, long-term survival among some HER2+ patients can also sometimes bring special challenges. Given the higher prevalence of brain metastases among HER2+ patients, Drs. Lin and Parsons also discuss current research on brain mets, along with areas of promising overall MBC research for each subtype.
Road to a Cure - Dr. Sara Hurvitz
The Road to a Cure series gets on the redeye to LA to have Senior Producer and Co-host, Victoria Goldberg and co-host Kate Pfitzer speak with Dr. Sara Hurvitz. She talks about her perspective on where we are as we work for a cure, the HER2+ studies she is excited about, and other research that is intriguing as it relates to all subtypes
Road to a Cure - Dr. Larry Norton
Our special series, Road to a Cure, makes its first stop at Memorial Sloan Kettering Cancer Center in New York, with an interview with Dr. Larry Norton. He is Senior Vice President in the Office of the President, and Deputy Director for Clinical and Translational Science in the Memorial Sloan Kettering Cancer Center. Dr. Norton’s also the Medical Director of the Evelyn H. Lauder Breast Center at MSK and a founder of the Breast Cancer Research Foundation. Senior Producer & Host Lisa Laudico and co-host Dr. Ellen Landsberger speak with Dr. Norton on what he sees happening with Metastatic Breast Cancer research today. They ask him about what lines of research are most exciting to him and also all about how he cares for his own mental health
Report Back from ASCO: What’s the Latest in Metastatic Breast Cancer
Are you living with ER+/HER2- or TNBC MBC and tired of hearing about new HER2 therapies and wondering when it will be your turn? Just after the meeting SHARE welcomed Dr. Timothy Pluard from University of Missouri-KC School of Medicine to a webinar highlighting promising data from trials and labs across the globe presented at the this year’s meeting,
Clinical Trials: The Patient Perspective Part 2
We know the challenges of trials and the barriers to recruitment as outlined in part 1. Now in Part 2 we explore solutions with patient advocates and medical professionals who are working to find ways forward. Clinical Trials from a Patient Perspective Part II. Let’s solve this.
Best of 3BlackDocs
We are excited to share another Best of from Season One. 3 Black Docs know how to keep it real and laugh and have fun. Dr. Karen Winkfield, Dr. Zanetta Lamar, and Dr. Tiffany Avery bring their professional take on racial disparities in healthcare and addressing structural barriers that lead to disparities in treatments and outcomes.
Report back from SABCS
Welcome to this bonus episode of Our MBC Life. It feels like a lifetime ago, but just a few weeks ago the world's largest breast cancer conference, the San Antonio Breast Cancer Symposium, was held. Just after the symposium SHARE welcomed Dr. Neil Iyengar from Memorial Sloan Kettering to a webinar where he shared information from SABCS highlighting both early-stage and metastatic research.
#TheRightDose
Anne Loeser and Dr. Aditya Bardia join the podcast to talk about the importance of getting The Right Dose.
All About Lobular Breast Cancer
Did you know that not ALL breast cancer can be detected by a lump? We are joined by Laurie Hutcheson of the Lobular Breast Cancer Alliance and researchers Steffi Oesterreich, PhD and Adrian Lee, PhD why ILC is difficult to research and what looks promising for the future.
Nancy U. Lin, MD
A conversation with Dr. Nancy Lin, Director of the Metastatic Breast Cancer Program at Dana-Farber Cancer Institute.